Dog Allergy Shots Cost: What Humans Pay for Dog SCIT

This page covers allergy shots (subcutaneous immunotherapy, or SCIT) given to HUMANS who are allergic to dogs — meaning your immune system produces IgE antibodies against dog proteins such as Can f 1 or Can f 5. This is entirely different from CYTOPOINT (lokivetmab), Apoquel (oclacitinib), or veterinary allergen-specific immunotherapy injected into the dog to treat the dog's own atopic dermatitis. Those products are prescribed by veterinarians for canine skin disease and are billed to pet insurance or paid out of pocket as a pet expense — typically $40–$80 per CYTOPOINT dose monthly. If you have arrived here looking for information about treating your dog's allergy, you are in the wrong place. For HUMAN dog-allergy shots, continue reading.

Without insurance at a freestanding allergist office, a typical maintenance visit (CPT 95117) runs $40–$200 billed, with cash retail averages of $85–$100 per visit in most US states per Fair Health and Sidecar Health benchmarks. Year 1 cash cost including skin testing and vial preparation is $1,850–$4,500 nationally; Year 2+ maintenance runs $700–$1,900/year. High-cost states like California, New York, and Massachusetts can push Year 1 cash costs to $4,500–$6,800. At a hospital outpatient department (HOPD), all of these figures can multiply 4–40× — the documented HOPD worst case for a 40-allergen panel is $24,400 at M Health Fairview Minneapolis (PBS NewsHour Weekend, 2024). Always ask your practice whether they are provider-based before scheduling.

Can f 5 is prostatic kallikrein, a protein produced exclusively in the prostate glands of intact male dogs — not in females or neutered males. Approximately 16.5% of dog-sensitized adults are monosensitized to Can f 5 alone (Ozuygur Ermis et al., Allergy 2023). In a randomized double-blind placebo-controlled challenge by Schoos et al. (JACI Pract 2020), all 7 Can f 5-monosensitized children tolerated female dog extract with no reaction. This means a patient who tests positive for dog allergy but is found — via component-resolved IgE testing — to react only to Can f 5 can potentially resolve their symptoms entirely by adopting a female or neutered male dog, rather than committing to a 3–5 year SCIT protocol costing $3,200–$10,000. Component testing is the prerequisite workup before starting dog SCIT.

No. The hypoallergenic breed claim is not supported by peer-reviewed evidence and should not be used to predict SCIT cost savings. Vredegoor et al. (JACI 2012;130[4]:904-9) tested 196 dogs across 11 breeds and found that so-called hypoallergenic breeds — including Labradoodles, Poodles, and Spanish Waterdogs — had significantly HIGHER Can f 1 levels in home dust (geometric mean 2.26 μg/g vs 0.77 μg/g in non-hypoallergenic breeds, P<0.001). Nicholas et al. (Am J Rhinol Allergy 2011) confirmed that detectable Can f 1 was present in 94% of homes regardless of breed. Switching to a Labradoodle will not reduce your allergen burden or eliminate the need for SCIT. The only meaningful breed/sex consideration is Can f 5 monosensitization, where adopting a female or neutered dog may be curative.

CPT codes are procedure-based, not allergen-specific — Medicare's 2025 allowed amounts of $11.97 for CPT 95117 (injection) and $13.91/dose for CPT 95165 (vial preparation) apply equally whether the antigen is dog, cat, grass, or dust mite. However, the clinical value delivered per dollar differs significantly. Cat-hair and cat-pelt extracts are FDA-standardized at 10,000 BAU/mL (the only mammalian allergens with FDA standardization), meaning each dose provides a predictable allergen load. Dog extracts are PNU-based (Greer, ALK-Abelló, Hollister-Stier) with significant lot-to-lot variability and no FDA standardization. A 2016 systematic review in Annals of Allergy, Asthma and Immunology of 17 dog SCIT trials concluded results showed 'poor and conflicting results of clinical efficacy, attributed to poor-quality extracts.' Same CPT, different evidence base.

Yes. Medicare Part B covers subcutaneous allergen immunotherapy (SCIT) for medically necessary allergic conditions including dog sensitization. The 2025 Medicare Part B deductible is $257 ($283 in 2026 per CMS announcement November 14, 2025). After the deductible, Medicare pays 80% of the allowed amount and the patient owes 20% coinsurance — approximately $2.39 per maintenance visit for CPT 95117 alone, or about $31.76 when a 10-dose vial preparation is included. A Medigap supplemental policy eliminates the 20% coinsurance entirely. Medicare does not cover sublingual immunotherapy (drops), only injectable SCIT. There are no network restrictions under Original Medicare, though clinical necessity documentation must be maintained per CMS LCD L36240.

A hospital outpatient department (HOPD) is an allergy practice that has been acquired by or classified as part of a hospital system. Patients treated at an HOPD receive two separate bills: the professional fee (billed under the Medicare Physician Fee Schedule) and a facility fee (billed under the hospital Outpatient Prospective Payment System). The facility fee is not capped by the contracted professional rate and can multiply the total bill dramatically. The clearest documented example: Kaitlin Johnson's 40-allergen skin-test panel at M Health Fairview in Minneapolis (an HOPD) was billed $24,400 in 2024 — while nearby freestanding clinics quoted $800–$1,827 for the same panel (PBS NewsHour Weekend, 2024). Before scheduling at any allergist office, ask the billing department: 'Is this practice classified as a provider-based facility or a hospital outpatient department?' and request the expected facility fee in writing.